PBDA

PROTALIX BIOTHERAP.DL-01

€2.165+€0.01 (0.46%)

Estimate

P/E

10.8

EPS

0.2

Beta

-0.088

Growth

Revenue, YoY

30.46%

Net income, YoY

2,264.63%

FCF, YoY

-99.28%

About the company

Ticker

PBDA

ISIN

US74365A3095

Country

Israel

Sector (GICS)

Healthcare

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.

Frequently asked questions

What sector does PROTALIX BIOTHERAP.DL-01 (PBDA) operate in?

PROTALIX BIOTHERAP.DL-01 belongs to the Healthcare sector and operates in the Biotechnology industry.

What is PROTALIX BIOTHERAP.DL-01 (PBDA) current stock price?

As of the latest data, PROTALIX BIOTHERAP.DL-01 stock price is €2.17, with a previous close of €2.16. PROTALIX BIOTHERAP.DL-01 gained €0.01 in the last trading session, representing a 0.46% increase.

What is PROTALIX BIOTHERAP.DL-01 (PBDA) current market capitalization?

PROTALIX BIOTHERAP.DL-01 market cap is approximately 174.44 million.

What is PROTALIX BIOTHERAP.DL-01 (PBDA) Earnings Per Share (EPS)?

The trailing EPS is €0.20.

What is PROTALIX BIOTHERAP.DL-01 (PBDA) Price-to-Earnings (P/E) ratio?

PROTALIX BIOTHERAP.DL-01 current P/E ratio is 10.83.

What is PROTALIX BIOTHERAP.DL-01 (PBDA) EBITDA?

PROTALIX BIOTHERAP.DL-01 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 5.04 million.

Does PROTALIX BIOTHERAP.DL-01 (PBDA) pay dividends?

No. PROTALIX BIOTHERAP.DL-01 does not pay a dividend.

When is PROTALIX BIOTHERAP.DL-01 (PBDA) next earnings report?

PROTALIX BIOTHERAP.DL-01 is expected to release its next earnings report on September 30, 2026.

What is PROTALIX BIOTHERAP.DL-01 (PBDA) beta (volatility) score?

PROTALIX BIOTHERAP.DL-01 has a beta of -0.088, indicating lower volatility than the overall market.